Egypt to launch EGTAP.com online platform to train tourism workforce: minister    Singapore's economy grows in Q2 '25    Gold prices dip slightly on Monday trading    Pakistan names Qatari royal as brand ambassador after 'Killer Mountain' climb    EU prepared to retaliate with €21b tariff package – Italy's FM    Al-Sisi reaffirms Egypt's commitment to African security, development at AU Mid-Year Summit    Dozens of Palestinians killed by Israeli fire near Gaza aid site    Health Ministry denies claims of meningitis-related deaths among siblings    Egypt's Contact insurance arms, Germany's GIZ partner on SMEs, gender equity    Egypt and Italy mark 50 years of science partnership, discuss future cooperation    Egypt establishes Real Estate Market Regulation Unit to oversee sector transparency    Egypt's Health Min. discusses drug localisation with Sandoz    Egypt, Mexico discuss environmental cooperation, combating desertification    Needle-spiking attacks in France prompt government warning, public fear    Foreign, housing ministers discuss Egypt's role in African development push    Egypt's EDA, Haleon discuss local market support    Korea Culture Week in Egypt to blend K-Pop with traditional arts    Egypt, France FMs review Gaza ceasefire efforts, reconstruction    CIB finances Giza Pyramids Sound and Light Show redevelopment with EGP 963m loan    Greco-Roman tombs with hieroglyphic inscriptions discovered in Aswan    Egypt reveals heritage e-training portal    Three ancient rock-cut tombs discovered in Aswan    Egypt condemns deadly terrorist attack in Niger    Sisi launches new support initiative for families of war, terrorism victims    Egypt's GAH, Spain's Konecta discuss digital health partnership    Egypt expands e-ticketing to 110 heritage sites, adds self-service kiosks at Saqqara    Egypt's Irrigation Minister urges scientific cooperation to tackle water scarcity    Palm Hills Squash Open debuts with 48 international stars, $250,000 prize pool    Egypt's Democratic Generation Party Evaluates 84 Candidates Ahead of Parliamentary Vote    On Sport to broadcast Pan Arab Golf Championship for Juniors and Ladies in Egypt    Golf Festival in Cairo to mark Arab Golf Federation's 50th anniversary    Germany among EU's priciest labour markets – official data    Cabinet approves establishment of national medical tourism council to boost healthcare sector    Egypt's PM follows up on Julius Nyerere dam project in Tanzania    Paris Olympic gold '24 medals hit record value    A minute of silence for Egyptian sports    Russia says it's in sync with US, China, Pakistan on Taliban    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Novartis: it's ‘too soon' to know whether malaria drug could be coronavirus vaccine
Published in Amwal Al Ghad on 27 - 03 - 2020

Swiss pharma giant Novartis on Friday has cautioned that it is "too soon" to be sure whether two anti-malaria drugs could be the definitive vaccine for the coronavirus.
Novartis is one of the main producers of one of the two anti-malaria drugs, hydroxychloroquine.
Trump touted at a White House press briefing last week the two anti-malaria drugs as a "game-changer" in the global fight against the coronavirus pandemic, noting that they had shown "very, very encouraging results.″
Chloroquine is a decades-old drug that was approved by the Food and Drug Administration (FDA) in 1949 as a treatment for malaria. Its derivative, hydroxychloroquine, is normally used by doctors as a treatment for rheumatoid arthritis and lupus.
"With hydroxychloroquine, what we know is in pre-clinical studies, the drug is quite active against the coronavirus but these are, of course, not in human beings — not in patients," Vas Narasimhan, chief executive of Novartis, has told CNBC's "Squawk Box Europe" via video link on Friday.
"I do think it is too soon to know for sure until we have properly controlled randomised studies," Narasimhan said.
"We hope over the next 18 months to two years, we can come back with a vaccine that will ultimately be the definitive way to deal with this pandemic."
As of Friday, over 537,000 people across the world had contracted the coronavirus according to data compiled by Johns Hopkins University, with 24,110 deaths.
To date, there are no vaccines or treatments available for the flu-like virus. However, trials are underway to find drugs that could serve this purpose.
One of those trials are led by the University of Minnesota as it will test to see whether hydroxychloroquine can prevent or reduce the severity of the coronavirus.


Clic here to read the story from its source.